Cambridge Biotech Founder Renata Osei Celebrates First FDA Drug Approval

Renata Osei's Cambridge-based biotech company, Meridian Cell Therapeutics, received its first FDA approval this week for a cell-based therapy treating a rare inherited blood disorder, a milestone Osei said validates more than a decade of work since she left a research position at MIT to start the company.

Osei founded Meridian eleven years ago with two former colleagues, initially operating out of a small incubator lab space before growing into a 90-person company headquartered in Kendall Square. The newly approved therapy targets a genetic blood disorder that affects a relatively small patient population, a category of rare disease treatments that has become an increasing focus for smaller biotech companies unable to compete for larger disease markets against major pharmaceutical firms.

"We picked this disease specifically because the patients had almost nothing available to them, not because it was going to be an easy regulatory path," Osei said. "It took us longer and cost more than we originally budgeted, but I don't think I could have justified spending a decade of my life on anything else."

The approval triggered a milestone payment from Meridian's pharmaceutical development partner, which will handle commercial manufacturing and distribution of the therapy. Osei said the company is using the proceeds to fund research on two additional rare disease programs currently in earlier stages of clinical trials.

Meridian Cell Therapeutics employs the majority of its staff at its Kendall Square headquarters, drawing heavily from the region's concentration of MIT- and Harvard-trained scientists. Osei said the company has no immediate plans to relocate despite recruiting interest from biotech hubs elsewhere in the country.